Record overview
Status and phase
Status: UNKNOWN
Phase: PHASE2
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition: Gastric Cancer
NCT05853172
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Unknown Status Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal
Results signal: Low Signal
Operational burden: None
Stopped reason
Context when available
No stop reason available in the current public record.